Alnylam (ALNY) slides 4% as valuation concerns linger after recent analyst reset

Alnylam Pharmaceuticals (ALNY) is down 4.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The drop looks consistent with a valuation-driven pullback after a recent high-profile analyst downgrade and price-target cut that reframed expectations for the stock. With no single, obvious company-specific headline driving the session, today’s move may also reflect investors continuing to digest Alnylam’s latest forward-looking pipeline and financial disclosures and trimming positions after a strong run.

Details:

Jefferies recently downgraded ALNY to Hold from Buy and cut its price target to $330, citing valuation and “priced for perfection” style concerns (March 16, 2026).

In a recent investor presentation, Alnylam highlighted FY 2025 revenue growth, 2026 full-year guidance, and multiple 2026 pipeline milestones that could keep expectations elevated (and volatility higher around resets).

A proxy statement filed in early April discussed executive compensation and long-term performance-based equity awards tied to multi-year stock performance targets, which can draw added attention to governance and incentive structure when the stock is volatile.

This could also be simple profit-taking: after large biotech rallies, even modest shifts in sentiment or rate expectations can pressure high-multiple names without fresh negative clinical or regulatory news.

Sources:

SEC, Alnylam Investor Relations, Investing.com, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ALNY Insider Trading Activity

$ALNY insiders have traded $ALNY stock on the open market 273 times in the past 6 months. Of those trades, 0 have been purchases and 273 have been sales.

Here’s a breakdown of recent trading of $ALNY stock by insiders over the last 6 months:

YVONNE GREENSTREET (Chief Executive Officer) has made 0 purchases and 60 sales selling 51,917 shares for an estimated $20,420,981.
KEVIN JOSEPH FITZGERALD (CSO & EVP, Head of Research) has made 0 purchases and 66 sales selling 24,469 shares for an estimated $9,634,419.
PUSHKAL GARG (EVP Chief R&D) has made 0 purchases and 53 sales selling 16,584 shares for an estimated $5,431,156.
JEFFREY V. POULTON (EVP, Chief Financial Officer) has made 0 purchases and 40 sales selling 9,696 shares for an estimated $3,224,118.
TOLGA TANGULER (EVP, Chief Commercial Officer) has made 0 purchases and 40 sales selling 7,376 shares for an estimated $2,424,943.
MELISSA MCLAUGHLIN (Chief Human Resources Officer) has made 0 purchases and 14 sales selling 3,910 shares for an estimated $1,274,342.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$ALNY Hedge Fund Activity

We have seen 409 institutional investors add shares of $ALNY stock to their portfolio, and 416 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,181,890 shares (-77.0%) from their portfolio in Q4 2025, for an estimated $867,628,558
REGENERON PHARMACEUTICALS, INC. removed 1,392,303 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $553,649,287
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,022,637 shares (-47.0%) from their portfolio in Q4 2025, for an estimated $406,651,603
FMR LLC removed 865,476 shares (-5.2%) from their portfolio in Q4 2025, for an estimated $344,156,531
BANK OF AMERICA CORP /DE/ removed 813,314 shares (-54.3%) from their portfolio in Q4 2025, for an estimated $323,414,312
INVESCO LTD. added 683,998 shares (+46.2%) to their portfolio in Q4 2025, for an estimated $271,991,804
JANE STREET GROUP, LLC removed 647,462 shares (-67.5%) from their portfolio in Q4 2025, for an estimated $257,463,264

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ALNY Analyst Ratings

Wall Street analysts have issued reports on $ALNY in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

B of A Securities issued a "Buy" rating on 01/30/2026
Barclays issued a "Overweight" rating on 01/28/2026
Needham issued a "Buy" rating on 01/12/2026
Truist Securities issued a "Buy" rating on 01/08/2026
Stifel issued a "Buy" rating on 12/11/2025
Piper Sandler issued a "Overweight" rating on 10/31/2025
Jefferies issued a "Buy" rating on 10/30/2025

To track analyst ratings and price targets for $ALNY, check out Quiver Quantitative's $ALNY forecast page.

$ALNY Price Targets

Multiple analysts have issued price targets for $ALNY recently. We have seen 17 analysts offer price targets for $ALNY in the last 6 months, with a median target of $465.0.

Here are some recent targets:

Danielle Brill from Truist Securities set a target price of $505.0 on 04/13/2026
Patrick R. Trucchio from HC Wainwright & Co. set a target price of $510.0 on 03/25/2026
Keay Nakae from Chardan Capital set a target price of $425.0 on 03/25/2026
Faisal Khurshid from Jefferies set a target price of $330.0 on 03/16/2026
Whitney Ijem from Canaccord Genuity set a target price of $429.0 on 02/17/2026
Ilya Zubkov from Freedom Capital Markets set a target price of $410.0 on 02/17/2026
Joseph Stringer from Needham set a target price of $510.0 on 02/12/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.